VEL 0230

Drug Profile

VEL 0230

Alternative Names: NC-2300; VEL-0230

Latest Information Update: 08 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Chemiphar
  • Developer Velcura Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple myeloma; Osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 08 Feb 2011 No development reported - Phase-I for Multiple myeloma in USA (PO)
  • 08 Feb 2011 No development reported - Phase-I for Osteoporosis in USA (PO)
  • 08 Feb 2011 No development reported - Phase-I for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top